New eye drops aim to quickly soothe dry eye pain

NCT ID NCT06493604

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested whether 0.25% reproxalap eye drops can reduce discomfort from dry eye disease better than a placebo. 116 adults with dry eye for at least 6 months used the drops six times over two days. The main goal was to measure changes in eye discomfort using a pain scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
reproxalap ophthalmic solution (0.25%)
What this could lead to
If it works, this could provide a new eye drop option to quickly ease discomfort from dry eye disease.
What could go wrong
This is a small, short-term trial (116 people, 2 days of treatment). Results may not apply to long-term use or all patients. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Andover Eye Associates

    Andover, Massachusetts, 01810, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.